Adherence to treatment of osteoporosis: a need for study (original) (raw)
Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 15:1003–1008 Article Google Scholar
Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928 ArticlePubMed Google Scholar
Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rtes in osteoporotic women: relationship to vertebral and non-vertebral fractures from 2 US claims databases. Mayo Clinic Proc 81:1013–1022 Article Google Scholar
Clowes JA, Peel NFA, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomised controlled trial. J Clin Endocrinol Metab 89:1117–1123 ArticlePubMedCAS Google Scholar
Yood RA, Emani S, Reid JI et al (2003) Compliance with pharmacological therapy for osteoporosis. Osteoporosis Int 14:965–968 ArticleCAS Google Scholar
Silverman S, Siris E, Abbott T et al (2003) Adherence to bisphosphonate therapy is associated with decreased non-vertebral osteoporotic fracture risk. J Bone Miner Res 20 (suppl 1):S286 Google Scholar
Weycker D, Macarios D, Edelsberg J et al (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporosis Int 17:1645–1652 ArticleCAS Google Scholar
Compston JE, Seeman E (2006) Compliance with osteoporosis therapy is the weakest link. Lancet 368:2005–2006 Article Google Scholar
Miller NH (1997) Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 102:43–49 ArticlePubMedCAS Google Scholar
Willey C, Redding C, Stafford J et al (2000) Stages of change for adherence with medication regimens for chronic diseases: development and validation of a measure. Clin Ther 22:858–871 ArticlePubMedCAS Google Scholar
Donovan JL (1995) Patient decision making. The missing ingredient in compliance research. Int J Technol Assess Health Care 11:443–455 PubMedCAS Google Scholar
Lutfey KE, Wishner WJ (1999) Beyond “compliance” is “adherence”. Improving the prospect of diabetes care. Diabetes Care 22:635–639 ArticlePubMedCAS Google Scholar
Henneman EA, Lee JL, Cohen JI (1995) Collaboration: a concept analysis. J Adv Nurs 21:103–109 ArticlePubMedCAS Google Scholar
Madden BP (1990) The hybrid model for concept development: its value for the study of therapeutic alliance. ANS Adv Nurs Sci 12:75–87 PubMedCAS Google Scholar
Mullen PD (1997) Compliance becomes concordance. B Med J 314:691–692 CAS Google Scholar
McCombs JS, Thiebaudet P, McLaughlin-Milet C et al (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287 ArticlePubMedCAS Google Scholar
Cooper A, Drake J, Brankin E, on behalf of the persist investigators (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once weekly alendronate: results from the PERSIST study. J Clin Practice 60:896–905 ArticleCAS Google Scholar
Cramer JA, Amonkar MM, Hebborn A et al (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453–1460 ArticlePubMedCAS Google Scholar
Fardellone P, Gaudin AF, Cotte FE (2005) Comparison of the persistence of daily and weekly bisphosphonates in female patients treated for osteoporosis. J Bone Miner Res 20 (Suppl 1):S285–S286 Google Scholar
Solomon DH, Avorn J, Katz et al (2005) Compliance with osteoporosis indications. Arch Intern Med 165:2414–2419 ArticlePubMed Google Scholar
Docherty SM, Goodley A, Steel SA (2005) Compliance and effect of bone protective treatment in elderly females: 5 year follow-up study. Rheumatology 44(Suppl 1):134 Google Scholar
Tosteson ANA, Grove MR, Hammond CS et al (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209–216 ArticlePubMed Google Scholar
Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporosis Int 14:259–262 CAS Google Scholar
Prowse D, McGetrick V, Thompson AJ et al (2005) Persistence with oral therapy is high amongst patients followed in a DGH osteoporosis. Clinical Rheumatology 44(Suppl):135 Article Google Scholar
Briesacher BA, Andrade S, Kahler K et al (2006) Economic impact of the previous year’s adherence with bisphosphonates. J Bone Miner Res 21(suppl 1):S171 Google Scholar
World Health Organization (2003) Adherence to long-term therapies: Evidence for action. WHO, Geneva, Switzerland Google Scholar
Lamberg L (2000) Patient-physician relationship critical even during brief “medication checks”. JAMA 284:29–31 ArticlePubMedCAS Google Scholar
Eraker SA, Kirscht JP, Becker MH (1984) Understanding and improving patient compliance. Ann Intern Med 100:258–268 PubMedCAS Google Scholar
Ammassari A, Trotta MP, Murri R et al (2002) Study group correlates and predictors of adherence to highly active antiretroviral therapy: Overview of Published. JAIDS 31(suppl 3):S123–S127 PubMed Google Scholar
McCloskey E, de Takats D, Orgee J et al (2005) Characteristics associated with non-persistence during daily therapy. Experience from the placebo wing of a community-based clinical trial. J Bone Miner Res 20(suppl 1):S282 Google Scholar
Claxton AJ, Cranmer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296–1310 ArticlePubMedCAS Google Scholar
Thompson P, Cooper C, Carr A (2005) Factors influencing adherence to bisphosphonates for osteoporosis. J Bone Miner Res 20 (suppl):S394 Google Scholar
Irvine J, Baker B, Smith J et al (1999) Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study Psychosom Med 61:566–575 PubMedCAS Google Scholar
Granger BB, Swedberg K, Ekman I, for the CHARM investigators (2005) Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 366:2005–2011 ArticlePubMedCAS Google Scholar
Delmas PD, Vrijens B, Eastell R et al (2007) Improving measurements of persistence on actonel treatment (IMPACT) investigators. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:296–304 ArticleCAS Google Scholar
Cramer JA, Silverman S (2006) Persistence with Bisphosphonate Treatment for Osteoporosis: Finding the root of the problem. Am J Med 119:S12–S17 ArticlePubMedCAS Google Scholar
Kanis JA et al (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11:1–256 Google Scholar
Stevenson M, Davies S (2006) DSU economic evaluation of pooled alendronate and risedronate compared with strontium ranelate, raloxifene, etidronate and teriparatide http://guidance.nice.org.uk/page.aspx?o=370643)
Spilker B (1991) Methods of assessing and improving patient compliance in clinical trials. In: Cramer JA, Spilker B (eds) (1991) Patient compliance in medical practice and clinical trials. Raven press, New York pp 37–56 Google Scholar
Melnikow J, Kiefe C (1994) Patient compliance and medical research. Issues in methodology. J Gen Int Med 9:96–105 ArticleCAS Google Scholar
Turbi C, Herrero-Beaumont G, Acebes JC et al (2004) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. Clin Ther 26:245–256 ArticlePubMedCAS Google Scholar
Farmer KC (1999) Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 21:1074–1090 ArticlePubMedCAS Google Scholar
Straka RJ, Fish JT, Benson SR et al (1997) Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug. Pharmacotherapy 17:126–132 PubMedCAS Google Scholar
Lee JY, Kusek JW, Greene PG et al (1996) Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertens 9:719–725 ArticlePubMedCAS Google Scholar
Mason BJ, Matsuyama JR, Jue SG (1995) Assessment of sulfonylurea adherence and metabolic control. Diabetes Educ 21:52–57 ArticlePubMedCAS Google Scholar
Paes AH, Bakker A, Soe-Agnie CJ (1998) Measurement of patient compliance. Pharm World Sci 20:73–77 ArticlePubMedCAS Google Scholar
Pullar T, Feely M (1990) Problems of compliance with drug treatment: new solutions? Pharm J 245:213–215 Google Scholar
Schwed A, Fallab CL, Burnier M et al (1999) Electronic monitoring of compliance to lipid-lowering therapy in clinical practice. J Clin Pharmacol 39:402–409 ArticlePubMedCAS Google Scholar